Back to Results
First PageMeta Content
Food and Drug Administration / Pharmaceuticals policy / Drug discovery / Orphan drug / Pharmaceutical industry / FDA Fast Track Development Program / Criticism of the Food and Drug Administration / Orphan Drug Act / Pharmaceutical sciences / Pharmacology / Clinical research


Document Date: 2013-12-24 07:18:09

Open Document

File Size: 189,15 KB

Share Result on Facebook

Company

Vertex Pharmaceuticals / Johnson & Johnson / YR YTD Pluristem Therapeutics Inc. / Seeking Alpha / Pluristem Therapeutics Inc. / /

Country

United States / /

Currency

USD / /

Event

FDA Phase / Person Communication and Meetings / /

IndustryTerm

intensified communications / patient groups / biotechnology / treatment for Buerger's Disease / pharmaceutical lobbyists / control / /

MedicalCondition

cuts / rare diseases / cancer / lymphoma / disease / Buerger's Disease / rare disease / very serious and life-threatening diseases / severe peripheral artery disease / onethird disease / diseases / aplastic anemia / fibrosis / blood disorder / /

MedicalTreatment

bone marrow transplant / /

Organization

Food and Drug Administration / FDA / /

Person

Sharon di Stefano / /

Position

author / keyword.. / /

Product

PLX / Pluristem Could Gain / /

PublishedMedium

Cancer Research / /

Technology

Alpha / biotechnology / /

URL

http /

SocialTag